Literature DB >> 20425569

Combination drugs for treating obesity.

Frank L Greenway1, George A Bray.   

Abstract

Although obesity is a chronic disease like hypertension and diabetes, obesity is not treated with drug combinations as are other chronic diseases. This is because orlistat and sibutramine, the two drugs approved for long-term treatment of obesity, do not result in additive weight loss when combined. This article discusses the history of combination drug therapy for treating obesity, the lessons learned from that experience, and describes the drug combinations now in development. One combination of two standardized dietary herbal supplements that result in clinically significant weight loss is also described. Obesity is poised to enter the era of combination drug therapy, as is now the routine in the treatment of other chronic diseases like hypertension and diabetes. The advent of combination drug therapy for obesity treatment offers hope for increasing the efficacy of obesity pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425569     DOI: 10.1007/s11892-010-0096-4

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  45 in total

1.  Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.

Authors:  M Weintraub; P R Sundaresan; M Madan; B Schuster; A Balder; L Lasagna; C Cox
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

2.  Meta-analysis: pharmacologic treatment of obesity.

Authors:  Zhaoping Li; Margaret Maglione; Wenli Tu; Walter Mojica; David Arterburn; Lisa R Shugarman; Lara Hilton; Marika Suttorp; Vanessa Solomon; Paul G Shekelle; Sally C Morton
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

Review 3.  The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent.

Authors:  F L Greenway
Journal:  Obes Rev       Date:  2001-08       Impact factor: 9.213

4.  Treatment of hypothalamic obesity with caffeine and ephedrine.

Authors:  Frank L Greenway; George A Bray
Journal:  Endocr Pract       Date:  2008-09       Impact factor: 3.443

5.  Rational design of a combination medication for the treatment of obesity.

Authors:  Frank L Greenway; M J Whitehouse; Maria Guttadauria; James W Anderson; Richard L Atkinson; Ken Fujioka; Kishore M Gadde; Alok K Gupta; Patrick O'Neil; Donald Schumacher; Diane Smith; Eduardo Dunayevich; Gary D Tollefson; Eckard Weber; Michael A Cowley
Journal:  Obesity (Silver Spring)       Date:  2008-11-06       Impact factor: 5.002

6.  A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.

Authors:  M Weintraub; J D Hasday; A I Mushlin; D H Lockwood
Journal:  Arch Intern Med       Date:  1984-06

7.  Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

Authors:  Frank L Greenway; Eduardo Dunayevich; Gary Tollefson; Janelle Erickson; Maria Guttadauria; Ken Fujioka; Michael A Cowley
Journal:  J Clin Endocrinol Metab       Date:  2009-10-21       Impact factor: 5.958

8.  The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial.

Authors:  A Astrup; L Breum; S Toubro; P Hein; F Quaade
Journal:  Int J Obes Relat Metab Disord       Date:  1992-04

9.  Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Authors:  Eric Ravussin; Steven R Smith; Julie A Mitchell; Reshma Shringarpure; Kevin Shan; Holly Maier; Joy E Koda; Christian Weyer
Journal:  Obesity (Silver Spring)       Date:  2009-06-11       Impact factor: 5.002

10.  Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study.

Authors:  Jesper Hallas; Lars Bjerrum; Henrik Støvring; Morten Andersen
Journal:  Am J Epidemiol       Date:  2008-08-27       Impact factor: 4.897

View more
  9 in total

1.  Treatment options for obesity and potential therapies on the horizon.

Authors:  Carol A Motycka; Erin St Onge; Shannon A Miller
Journal:  P T       Date:  2011-05

Review 2.  Novel strategy for the use of leptin for obesity therapy.

Authors:  Charmaine S Tam; Virgile Lecoultre; Eric Ravussin
Journal:  Expert Opin Biol Ther       Date:  2011-09-13       Impact factor: 4.388

3.  Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model.

Authors:  E M Kaptein; L S Chan; J S Kaptein
Journal:  Eat Weight Disord       Date:  2012-09-24       Impact factor: 4.652

4.  Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations.

Authors:  N-C Liang; N T Bello; T H Moran
Journal:  Int J Obes (Lond)       Date:  2012-02-07       Impact factor: 5.095

5.  Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice.

Authors:  Christoffer Clemmensen; Brian Finan; Katrin Fischer; Robby Zachariah Tom; Beata Legutko; Laura Sehrer; Daniela Heine; Niklas Grassl; Carola W Meyer; Bart Henderson; Susanna M Hofmann; Matthias H Tschöp; Lex H T Van der Ploeg; Timo D Müller
Journal:  EMBO Mol Med       Date:  2015-03       Impact factor: 12.137

6.  Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide.

Authors:  Samantha M Fortin; Jack Chen; Matthew R Hayes
Journal:  Physiol Behav       Date:  2020-03-14

Review 7.  Phentermine and topiramate for the management of obesity: a review.

Authors:  Gina Cosentino; Ariane O Conrad; Gabriel I Uwaifo
Journal:  Drug Des Devel Ther       Date:  2011-04-05       Impact factor: 4.162

Review 8.  Combinations of drugs in the Treatment of Obesity.

Authors:  Bruno Halpern; Eduardo S L Oliveira; André M Faria; Alfredo Halpern; Maria Edna de Melo; Cintia Cercato; Marcio C Mancini
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-27

9.  An intraoral device for weight loss: initial clinical findings.

Authors:  Paul A Brunton; Jithendra Ratnayake; H Jonathan Bodansky; Li Mei; Arthi Veerasamy; Richard Hall
Journal:  Br Dent J       Date:  2021-06-25       Impact factor: 2.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.